Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMLI, Fludarabine, and Melphalan as Conditioning for AlloHCT in High-Risk Acute Leukemia or MDS
NCT03494569Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Jul 2018
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fludarabine and melphalan in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by City of Hope. Primary endpoint: Incidence of toxicity at 2 years. Started Jul 2018; status: suspended.
02
Drugs
fludarabinemelphalan
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03494569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494569.